Search

Lebrikizumab

years and older with a body weight of at least 40 kg. … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12

Molybdenum

Molybdenum is a chemical element with symbol Mo and atomic number 42. As it is not a naturally occuring free metal on Earth, molybdenum is found only in various oxidation states in minerals. … It is an essential trace dietary element and acts as a critical cofactor in several molybdenum-dependent enzymes that are involved in important cellular reactions and pathways, including xanthine oxidoreductase

Fluorocholine F-18

Polysorbate 20

Polysorbate 20 is a polysorbate-type nonionic surfactant used in many commercial, household and pharmaceutical products. It is composed of 20 repeated units of polyethylene glycol via ethoxylation. … Polysorbate 20 is a wetting agent in food products, as well as washing agent, stabilizer and solubilizer in labratory assays and industrial applications.

Sunvozertinib

receptor (EGFR) exon 20 insertion mutations. … [A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor

Benzoic acid

As the sodium salt form, sodium benzoate is used as a treatment for urea cycle disorders due to its ability to bind amino acids. … This leads to excretion of these amino acids and a decrease in ammonia levels. Recent research shows that sodium benzoate may be beneficial as an add-on therapy (1 gram/day) in schizophrenia.

Quinupristin

The combination of the two components acts synergistically and is more effective in vitro than each component alone. … Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.

Pralsetinib

[A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated

Piperonyl butoxide

Piperonyl butoxide (PBO) is an organic compound used as a component of pesticide formulations. It is used for the treatment of head, pubic (crab), and body lice. Piperonyl butoxide is a synergist.

Lanatoside C